Unicycive Therapeutics shares rise 1.30% premarket after reporting positive OLC pivotal study data and cash runway into 2H 2026.

Unicycive Therapeutics, Inc. rose 1.30% in premarket trading, with the company reporting its financial results for the second quarter and six months ended June 30, 2025. The company reported a net loss of USD 6.45 million for the second quarter, compared to a net income of USD 9.86 million a year ago. Additionally, Unicycive Therapeutics announced a Type A Meeting requested with the U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC), and ended Q2 with $22.3 million of cash with expected runway into the second half of 2026.